You have 1 action to finish to complete your account. Customize your experience by selecting your interests on the Personalization page

No matches

99 search results for: patient burden

expert video

CSU Burden Related to Chronicity and Patient Journey

2 min

Dermatology

Join Professor Hide as he describes the disease burden and treatment challenges experienced by patients with chronic spontaneous urticaria.

<b>Burden</b>s Experienced by Pediatric Asthma <b>Patient</b>s and Their Caregivers

expert video

Burdens Experienced by Pediatric Asthma Patients and Their Caregivers

3 min

Pulmonology

Drs. Michael Blaiss and Bob Geng discuss the burdens experienced by pediatric severe asthma patients and their caregivers.

Most <b>Burden</b>some Symptoms Rated by PN <b>Patient</b>s

expert video

Most Burdensome Symptoms Rated by PN Patients

1 min

Dermatology

Dr. Chovatiya discusses the impact of pruritus on patients with PN.

Type 2 Inflammatory Disease Trajectories: Unraveling Patterns of Disease Development and <b>Burden</b> in Pediatric <b>Patient</b>s

expert video

Type 2 Inflammatory Disease Trajectories: Unraveling Patterns of Disease Development and Burden in Pediatric Patients

15 min

Type 2 Inflammation

Dr. Leonard Bacharier presents potential disease trajectories and burden for pediatric patients with type 2 inflammatory diseases.

Explore the Global <b>Burden</b> of Pediatric AD (PEDISTAD)

interactivity

Explore the Global Burden of Pediatric AD (PEDISTAD)

15 min

Dermatology

This interactive tool allows you to explore the global burden of AD in pediatric patients <12 years from the PEDISTAD Study.

ERS-ISIAN 2023 | From Endotype to Phenotype: Linking Pathophysiology to <b>Burden</b> and Clinical Management for <b>Patient</b>s with Uncontrolled and/or Severe CRSwNP

expert video

ERS-ISIAN 2023 | From Endotype to Phenotype: Linking Pathophysiology to Burden and Clinical Management for Patients with Uncontrolled and/or Severe CRSwNP

9 min

Rhinology

Prof. Peter Hellings discusses the interconnection between the pathophysiology, burden and clinical management of uncontrolled and/or severe CRSwNP

expert video

The Path to Nodules: Type 2 Inflammation at the Core of Chronic Itch and Fibrosis in Prurigo Nodularis

11 min

Type 2 Inflammation

Join Dr. Shawn Kwatra in discussing the diverse clinical presentations of PN and the role of type 2 inflammation in disease pathogenesis.

From Endotype to Phenotype: Linking Pathophysiology to <b>Burden</b> and Clinical Management for <b>Patient</b>s with Uncontrolled and/or Severe CRSwNP

expert video

From Endotype to Phenotype: Linking Pathophysiology to Burden and Clinical Management for Patients with Uncontrolled and/or Severe CRSwNP

9 min

Rhinology

Prof. Peter Hellings discusses the interconnection between the pathophysiology, burden and clinical management of uncontrolled and/or severe CRSwNP.

Prurigo Nodularis: The <b>Patient</b> Journey

interactivity

Prurigo Nodularis: The Patient Journey

5 min

Dermatology

An interactive tool highlighting the disease burden, impact and management of prurigo nodularis throughout the patient journey before diagnosis, during diagnosis and during treatment.

ADVENT is a global medical education non-promotional program by Sanofi and Regeneron. This website is intended only for duly authenticated healthcare professionals in Algeria, Argentina, Australia, Austria, Bahrain, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Costa Rica, Croatia, Czech Republic, Denmark, Dominican Republic, Ecuador, Egypt, Estonia, Finland, France, Germany, Greece, Guatemala, Hong Kong, Hungary, Iceland, India, Israel, Italy, Japan, Kuwait, Latvia, Lebanon, Lithuania, Macau, Malaysia, Norway, Oman, Panama, Peru, Poland, Portugal, Qatar, Romania, Saudi Arabia, Singapore, Slovenia, South Africa, South Korea, Spain, Sudan, Sweden, Switzerland, Taiwan, Thailand, The Netherlands, Turkey, United Arab Emirates, or the United States of America.

For healthcare professionals in Algeria: Please read the additional Terms of Use.

Sanofi and Regeneron are global leaders in pharmaceutical development, each with a long history of supporting frontline physicians to improve human health and reduce the burden of disease. Driven by the same commitment to patients and their families, Sanofi and Regeneron have partnered to take on type 2 inflammation and the range of chronic conditions in which excessive inflammation plays a role.

Country/region: MacauChange country/region